Skip to main content

Advertisement

Log in

Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era

  • Epidemiology Report
  • Published:
Journal of NeuroVirology Aims and scope Submit manuscript

Abstract

Whereas most AIDS-related neurologic disorders have reduced incidence since HAART therapy was introduced, we find that the incidence of progressive multifocal leukoencephalopathy (PML) did not significantly differ between the pre-HAART and the HAART period (OR 0.78; 95% CI 0.41–1.50). These findings were confirmed by the preliminary results of the Italian Register Investigative Neuro AIDS (IRINA) Study, a prospective multicenter study started in January 2000, which showed that PML was the second most frequently diagnosed neurologic disorder after TE. A similar proportion of cases were found in HAART-naöve and HAART-experienced patients in our experience. PML was more common in the presence of HIV RNA > 500 copies/ml. Most of the cases occurring in HAART-exposed patients developed within the first 6 months of therapy. As others have reported, we find a prolonged survival in PML subjects prescribed HAART (245 days in the group treated with HAART versus 66 days in the group not treated with HAART; P at log rank = 0.001). However despite the survival benefit, AIDS-associated PML still has a serious prognosis. In fact, PML had the lowest 1-year survival probability of any cerebral disorder in our study (P = 0.0005). Our findings also confirm that CSF JCV DNA burden at baseline is a useful prognostic indicator with a threshold of 4.7 log10 JCV copies/ml (P at log rank = 0.01) in our experience. CSF JCV DNA load at 4 weeks of follow-up and clearance of JCV-DNA from CSF are associated with a better neurologic outcome and a longer survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ammassari A, Cingolani A, Pezzotti P, De Luca A, Murri R, Giancola ML, Larocca LM, Antinori A (2000). AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology 55: 1194–1200.

    CAS  PubMed  Google Scholar 

  • Antinori A, Ammassari A, Cinque P, Toma L, Govoni A, Soldani F, Giancola ML, Grisetti S, Pierotti C, Fausti C, Finazzi MG, Bini T, Del Grosso B, Cristiano L, Corsi P, Fasulo G, Mena M, Guaraldi G, Arcidiacono MI, Monno L, Gigli B, Fibbia GC, Gentile M, Mastroianni A, Speranza F, d’Arminio Monforte A, Rezza G, Ippolito G (2001a). Shift of prevalence and selected characteristics in HIV-1 related neurologic disorders in HAART era: data from Italian Register Investigative Neuro AIDS (IRINA). 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 4–8, 2001 (Abstract 8).

  • Antinori A, Giancola ML, Soldani F, Grisetti S, Galgani S, Tozzi V, Gigli B, Gentile M, Busi E, Martini F, Calcaterra S, Girardi E, Ippolito G (2001b). Long term survival in HIV-1 infected patients with neurological disorders treated with HAART: analysis of clinical, immunological and virological predictors. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 4–8, 2001 (Abstract 599).

  • Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J (1997). Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277: 112–116.

    Article  CAS  PubMed  Google Scholar 

  • Beck EJ, Mandalia S, Williams I, Power A, Newson R, Molesworth A, Barlow D, Easterbrook P, Fisher M, Innes J, Kinghorn G, Mandel B, Pozniak A, Tang A, Tomlinson D for the National Prospective Monitoring System Steering Group (1999). Decreasedmorbidity and use of hospital services in English HIV-infected individuals with increased uptake of antiretroviral therapy 1996–1997. AIDS 13: 2157–2164.

    Article  CAS  PubMed  Google Scholar 

  • Berger JR, Kaszovitz B, Donovan Post MJ, Dickinson G (1987). Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. Ann Intern Med 107: 78–87.

    CAS  PubMed  Google Scholar 

  • Berger JR, Levy RM, Flomenhoft D, Dobbs M (1998). Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 44: 341–349.

    Article  CAS  PubMed  Google Scholar 

  • Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB (1997). Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 11: 1731–1738.

    Article  CAS  PubMed  Google Scholar 

  • Cinque P, Casari S, Bertelli D (1998). Progressive multifocal leukoencephalopathy, HIV, and Highly Active Antiretroviral Therapy. N Engl J Med 339: 848–849.

    Article  CAS  PubMed  Google Scholar 

  • Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ, Marra CM, Francis GS, McArthur JC, Tyler KL, Tselis AC, Hyslop NE (1999). HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52: 623–625.

    CAS  PubMed  Google Scholar 

  • Collazos J, Mayo J, Martinez E, Blanco MS (1999). Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. AIDS 13: 1426–1428.

    Article  CAS  PubMed  Google Scholar 

  • d’Arminio Monforte A, Duca PG, Vago L, Grassi MP, Moroni M (2000). Decreasing incidence of CNS AIDS-defining events associated with antiretroviral therapy. Neurology 54: 1856–1859.

    PubMed  Google Scholar 

  • De Luca A, Giancola ML, Ammassari A, Grisetti S, Paglia MG, Gentile M, Cingolani A, Murri R, Liuzzi G, d’Arminio Monforte A, Antinori A (2000). The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 182: 1077–1083.

    Article  PubMed  Google Scholar 

  • De Luca A, Giancola ML, Cingolani A, Ammassari A, Gillini L, Murri R, Antinori A (1999). Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 28: 624–628.

    Article  PubMed  Google Scholar 

  • Dworkin MS, Wan PC, Hanson DL, Jones JL, and the Adult and Adolescent Spectrum of HIV Disease Project (1999). Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis 180: 621–625.

    Article  CAS  PubMed  Google Scholar 

  • Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, Abramson I, Atkinson H, Grant I, McCutchan JA, and the HIV Neurobehavioral Research Center Group (1997). Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Ann Neurol 42: 679–688.

    Article  CAS  PubMed  Google Scholar 

  • Fong IW, Toma E, and the Canadian PML Study Group (1995). The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Clin Infect Dis 20: 1305–1310.

    CAS  PubMed  Google Scholar 

  • Gasnault J, Taoufik Y, Goujard C, Kousignian P, Abbed K, Boue F, Dussaix E, Delfraissy JF (1999). Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. J NeuroVirol 5: 421–429.

    Article  CAS  PubMed  Google Scholar 

  • Giancola ML, Tartaglione T, Ammassari A, Settecasi C, Cingolani A, Larussa D, Murri R, De Luca A (2000). Neurological and virologic predictors of survival in AIDS-associated progressive multifocal leukoencephalopathy (PML): the role of HAART. XIII International Conference on AIDS. Durban, July 9–14, 2000. (Abstract TuOrB358.)

  • Giudici B, Vaz B, Bossolasco S, Casari S, Brambilla AM, Luke W, Lazzarin A, Weber T, Cinque P (2000). Highly Active Antiretroviral Therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 30: 95–99.

    Article  CAS  PubMed  Google Scholar 

  • Koralnik IJ, Boden D, Mai VX, Lord CI, Letvin NL (1999). JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 52: 253–260.

    CAS  PubMed  Google Scholar 

  • Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A, and the Swiss Cohort Study (1999). AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 282: 2220–2226.

    Article  CAS  PubMed  Google Scholar 

  • Mayo J, Collazos J, Martinez E (1998). Progressive multifocal leukoencephalopathy following initiation of highly active antiretroviral therapy. AIDS 12: 1720–1722.

    CAS  PubMed  Google Scholar 

  • Pallella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD, and the HIV Outpatient Study Investigators (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338: 853–860.

    Article  Google Scholar 

  • Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Seines OA, Miller EN, Becker JT, Cohen B, McArthur JC, and the Multicenter AIDS Cohort Study (2001). HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology 56: 257–260.

    CAS  PubMed  Google Scholar 

  • Tantisiriwat W, Tebas P, Clifford DB, Powderly J, Fichtenbaum CJ (1999). Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 28: 1152–1154.

    Article  CAS  PubMed  Google Scholar 

  • Taoufik Y, Delfraissy JF, Gasnault J (2000). Highly active antiretroviral therapy does not improve survival of patients with high JC virus load in the cerebrospinal fluid at progressive multifocal leukoencephalopathy diagnosis. AIDS 14: 758–759.

    Article  CAS  PubMed  Google Scholar 

  • Taoufik Y, Gasnault J, Karaterki A, Ferey MP, Marchadier E, Goujard C, Lannuzel A, Delfraissy JF, Dussaix E (1998). Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Infect Dis 178: 1816–1820.

    Article  CAS  PubMed  Google Scholar 

  • Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boué F, Billaud E, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database on HIV (1999). Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. AIDS 13: 1881–1887.

    Article  CAS  PubMed  Google Scholar 

  • Yiannoutsos CT, Major EO, Curfman B, Jensen PN, Gravell M, Hou J, Clifford D, Hall CD (1999). Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsyproven progressive multifocal leukoencephalopathy. Ann Neurol 45: 816–820.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andrea Antinori.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Antinori, A., Ammassari, A., Giancola, M.L. et al. Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. Journal of NeuroVirology 7, 323–328 (2001). https://doi.org/10.1080/13550280152537184

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1080/13550280152537184

Keywords

Navigation